BLA 761356: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761356's history or Gan & Lee Pharmaceuticals's company page.
On Apr 12, 2024, FDA declined to approve BLA 761356 (BLA 761356) from Gan & Lee Pharmaceuticals in its present form, citing product quality, facility inspections. openFDA lists it as not yet approved.
- Letter date: Apr 12, 2024
- Application: BLA 761356
- Since then: Not approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDASilver Spring, MD 20993 www.fda.gov U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov FACILITY INSPECTIONS 6. Following pre-license inspection 0 a listed in this application, conveyed deficiencies to the representative of the facility. Your...… openFDA did not return the full text just now. Open it in the letter search.
Gan & Lee Pharmaceuticals's Other Letters
Newest first- BLA 761357Mar 26, 2024 · BLA 761357 · not approved
Record
- Company
- Gan & Lee Pharmaceuticals
- Application
- BLA 761356
- Status in openFDA
- Unapproved
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters